Assignee
BIAL PORTELA & CA SA
PT·18 granted patents·45 pending applications·39 citations·filing 2005–2024
Top patents by PatentIndex Score
63 records- 0189US9126988B2Intermediate for preparing a catechol-O-methyltransferase inhibitorBIAL PORTELA & CA SA·Filed 2012·Granted Sep 8, 2015·17 cites·30 claims
- 0286US8372431B2Pharmaceutical composition comprising licarbazepine acetateBIAL PORTELA & CA SA·Filed 2008·Granted Feb 12, 2013·11 cites·86 claims
- 0382US10023541B2Urea compounds and their use as enzyme inhibitorsBIAL PORTELA & CA SA·Filed 2016·Granted Jul 17, 2018·4 cites·8 claims
- 0481US2025275934A1Medicaments for slowing parkinson's diseaseBIAL PORTELA & CA SA·Filed 2024·Application pending·0 cites
- 0581US2025276963A1Administration regime for nitrocatecholsBIAL PORTELA & CA SA·Filed 2024·Application pending·0 cites
- 0680US2025262196A1Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereofBIAL PORTELA & CA SA·Filed 2024·Application pending·0 cites
- 0777US10675287B2Methods of treatment of partial onset seizures using eslicarbazepine acetateBIAL PORTELA & CA SA·Filed 2019·Granted Jun 9, 2020·0 cites·23 claims
- 0877US2022388999A1Nitrocatechol derivatives as comt inhibitorsBIAL PORTELA & CA SA·Filed 2022·Application pending·0 cites
- 0976US7667075B2Sulphonylated diphenylethylenediamines, method for their preparation and use in transfer hydrogenation catalysisBIAL PORTELA & CA SA·Filed 2005·Granted Feb 23, 2010·3 cites·20 claims
- 1075US7834177B2Method for preparation of 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamideBIAL PORTELA & CA SA·Filed 2006·Granted Nov 16, 2010·4 cites·15 claims
- 1175US2023355560A1Medicaments for slowing parkinson's diseaseBIAL PORTELA & CA SA·Filed 2023·Application pending·0 cites
- 1274US2021261533A11,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylaseBIAL PORTELA & CA SA·Filed 2021·Application pending·0 cites
- 1374US2023129254A1Methods of treatment of partial onset seizures using eslicarbazepine acetateBIAL PORTELA & CA SA·Filed 2022·Application pending·0 cites
- 1474US2024000762A1Treatment regimens for early idiopathic parkinson's diseaseBIAL PORTELA & CA SA·Filed 2023·Application pending·0 cites
- 1573US11364247B2Methods of treatment of partial onset seizures using eslicarbazepine acetateBIAL PORTELA & CA SA·Filed 2020·Granted Jun 21, 2022·0 cites·22 claims
- 1673US2023390267A1Treatment regimens for early idiopathic parkinson's diseaseBIAL PORTELA & CA SA·Filed 2023·Application pending·0 cites
- 1770US10695354B2Methods of treatment of partial onset seizures using eslicarbazepine acetateBIAL PORTELA & CA SA·Filed 2019·Granted Jun 30, 2020·0 cites·27 claims
- 1870US2020102295A1Nitrocatechol derivatives as comt inhibitorsBIAL PORTELA & CA SA·Filed 2019·Application pending·0 cites
- 1968US12129247B2Administration regime for nitrocatecholsBIAL PORTELA & CA SA·Filed 2018·Granted Oct 29, 2024·0 cites·17 claims
- 2068US10702536B2Methods of treatment of partial onset seizures using eslicarbazepine acetateBIAL PORTELA & CA SA·Filed 2017·Granted Jul 7, 2020·0 cites·30 claims
- 2168US2021322436A1Pharmaceutical composition comprising licarbazepine acetateBIAL PORTELA & CA SA·Filed 2021·Application pending·0 cites
- 2266US2022017523A1BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORSBIAL PORTELA & CA SA·Filed 2021·Application pending·0 cites
- 2365US2021186910A1Medicaments for slowing parkinson's diseaseBIAL PORTELA & CA SA·Filed 2020·Application pending·0 cites
- 2464US10912781B2Pharmaceutical composition comprising licarbazepine acetateBIAL PORTELA & CA SA·Filed 2017·Granted Feb 9, 2021·0 cites·25 claims
- 2564US2019322648A11,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylaseBIAL PORTELA & CA SA·Filed 2019·Application pending·0 cites
- 2664US2023138795A1Dopamine-b-hydroxylase inhibitorsBIAL PORTELA & CA SA·Filed 2022·Application pending·0 cites
- 2763US11046654B2Urea compounds and their use as enzyme inhibitorsBIAL PORTELA & CA SA·Filed 2018·Granted Jun 29, 2021·0 cites·14 claims
- 2863US2026053782A1Treatment regimens for parkinson's diseaseBIAL PORTELA & CA SA·Filed 2023·Application pending·0 cites
- 2963US2014288058A1Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of useBIAL PORTELA & CA SA·Filed 2014·Application pending·0 cites
- 3062US2021023067A1Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereofBIAL PORTELA & CA SA·Filed 2020·Application pending·0 cites
- 3161US11078163B2Processes for the synthesis of substituted urea compoundsBIAL PORTELA & CA SA·Filed 2019·Granted Aug 3, 2021·0 cites·12 claims
- 3261US2010048538A1Therapeutical Uses of EslicarbazepineBIAL PORTELA & CA SA·Filed 2008·Application pending·0 cites
- 3360US2009326274A1Sulphonylated Diphenylethylenediamines, Method for Their Preparation and Use in Transfer Hydrogenation CatalysisBIAL PORTELA & CA SA·Filed 2009·Application pending·0 cites
- 3459US2020078328A1Medicaments for slowing parkinson's diseaseBIAL PORTELA & CA SA·Filed 2019·Application pending·0 cites
- 3558US2021315824A1Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the sameBIAL PORTELA & CA SA·Filed 2020·Application pending·0 cites
- 3658US2020255412A1Imidazolecarboxamides and Their Use as FAAH InhibitorsBIAL-PORTELA & CA SA·Filed 2019·Application pending·0 cites
- 3757US2024066015A1Treatment of pain associated with parkinson's diseaseBIAL PORTELA & CA SA·Filed 2021·Application pending·0 cites
- 3856US10501447B2Imidazolecarboxamides and their use as FAAH inhibitorsBIAL PORTELA & CA SA·Filed 2014·Granted Dec 10, 2019·0 cites·15 claims
- 3955US2013150348A1CompositionBIAL PORTELA & CA SA·Filed 2013·Application pending·0 cites
- 4055US2013190276A1Use of 5-h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disordersBIAL PORTELA & CA SA·Filed 2013·Application pending·0 cites
- 4154US2013331416A1Dosage regimen for comt inhibitorsBIAL PORTELA & CA SA·Filed 2013·Application pending·0 cites
- 4254US2018228812A1Therapeutical uses of eslicarbazepineBIAL PORTELA & CA SA·Filed 2017·Application pending·0 cites
- 4352US2015313910A1Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disordersBIAL PORTELA & CA SA·Filed 2015·Application pending·0 cites
- 4452US2010217009A1Process for Preparing Chroman DerivativesBIAL PORTELA & CA SA·Filed 2008·Application pending·0 cites
- 4552US2019241545A11,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung InjuryBIAL PORTELA & CA SA·Filed 2019·Application pending·0 cites
- 4652US2023241046A1Solid dispersion of opicaponeBIAL PORTELA & CA SA·Filed 2021·Application pending·0 cites
- 4751US2010113799A1Process for the Preparation of (R) - 5 - (2-Aminoethyl) -1- (6, 8-Difluorochroman-3-YL) -1,3-Dihydroimidazole-2-ThioneBIAL PORTELA & CA SA·Filed 2008·Application pending·0 cites
- 4850US2011166360A1Catalytic Process for Asymmetric HydrogenationBIAL PORTELA & CA SA·Filed 2009·Application pending·0 cites
- 4950US2010292482A1Novel precursorsBIAL PORTELA & CA SA·Filed 2008·Application pending·0 cites
- 5049US2021169856A1Formulations comprising dopamine-b-hydroxylase inhibitors and methods for their preparationBIAL PORTELA & CA SA·Filed 2019·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIAL PORTELA & CA SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →